Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
|
|
KalVista Pharmaceuticals, Inc. (KALV)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/28/2023 |
4
| Unkart Edward W (Director) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Granted 10,000 options to buy
@ $10.08, valued at
$100.8k
|
|
| 09/28/2023 |
4
| Pereira Brian JG (Director) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Granted 10,000 options to buy
@ $10.08, valued at
$100.8k
|
|
| 09/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/21/2023 |
4
| Audhya Paul K. (Chief Medical Officer) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Sold 8,020 shares
@ $10.7288, valued at
$86k
Exercised 2,418 restricted stock units
@ $0
Exercised 4,028 restricted stock units
@ $0
Exercised 12,083 rights
@ $0 |
|
| 08/21/2023 |
4
| Feener Edward P. (Chief Scientific Officer) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Sold 4,976 shares
@ $10.7287, valued at
$53.4k
Exercised 1,773 restricted stock units
@ $0
Exercised 2,430 restricted stock units
@ $0
Exercised 7,291 rights
@ $0 |
|
| 08/21/2023 |
4
| Yea Christopher (Chief Development Officer) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Sold 7,142 shares
@ $10.7287, valued at
$76.6k
Exercised 1,773 restricted stock units
@ $0
Exercised 2,430 restricted stock units
@ $0
Exercised 7,291 rights
@ $0 |
|
| 08/21/2023 |
4
| Palleiko Benjamin L (President, CFO, CBO & Sec'y) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Sold 13,067 shares
@ $10.7287, valued at
$140.2k
Exercised 6,944 restricted stock units
@ $0
Exercised 2,418 restricted stock units
@ $0
Exercised 20,833 rights
@ $0 |
|
| 08/21/2023 |
4
| Crockett Thomas Andrew (CEO) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Sold 14,876 shares
@ $10.7288, valued at
$159.6k
Exercised 6,944 restricted stock units
@ $0
Exercised 5,805 restricted stock units
@ $0
Exercised 20,833 rights
@ $0 |
|
| 08/14/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 08/14/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/14/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/04/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 07/07/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"KalVista Pharmaceuticals Inc. Condensed Consolidated Balance Sheets April 30, April 30, 2023 2022 Assets Current assets: Cash and cash equivalents $56,238 $30,732 Marketable securities 93,137 135,470 Research and development tax credit receivable 16,568 14,098 Prepaid expenses and other current assets 6,383 13,347 Total current assets 172,326 193,647 Property and equipment, net 2,948 2,178 Right of use assets 7,822 7,862 Other assets 106 193 Total assets $183,202 $203,880 Liabilities and stockholders' equity Current liabilities: Accounts payable $4,817 $3,638 Accrued expenses 9,128 6,961 Lease liability - current portion 1,087 977 Total current liabilities 15,032 11,576 Long-term liabilities: Lease liability - net of current portion 7,145 7,211 Total long-term liabilities 7,145 7,211stock..." |
|
| 07/07/2023 |
10-K
| Annual Report for the period ended April 30, 2023 |
| 05/22/2023 |
4/A
| Yea Christopher (Chief Development Officer) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Exercised 2,430 options to buy
@ $0 |
|
| 05/22/2023 |
4/A
| Palleiko Benjamin L (President, CFO, CBO & Sec'y) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Exercised 6,944 options to buy
@ $0 |
|
| 05/22/2023 |
4/A
| Feener Edward P. (Chief Scientific Officer) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Exercised 2,430 options to buy
@ $0 |
|
| 05/22/2023 |
4/A
| Crockett Thomas Andrew (CEO) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Exercised 6,944 options to buy
@ $0 |
|
| 05/22/2023 |
4/A
| Audhya Paul K. (Chief Medical Officer) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Exercised 4,027 options to buy
@ $0 |
|
| 05/22/2023 |
4
| Palleiko Benjamin L (President, CFO, CBO & Sec'y) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Granted 40,000 options to buy
@ $10.4, valued at
$416k
|
|
| 05/19/2023 |
4
| Yea Christopher (Chief Development Officer) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Sold 2,604 shares
@ $10.1444, valued at
$26.4k
Granted 29,166 restricted stock units
@ $0
Exercised 2,431 restricted stock units
@ $0
Exercised 1,774 restricted stock units
@ $0 |
|
| 05/19/2023 |
4
| Palleiko Benjamin L (President, CFO, CBO & Sec'y) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Sold 4,037 shares
@ $10.1444, valued at
$41k
Granted 83,334 restricted stock units
@ $0
Exercised 6,945 restricted stock units
@ $0
Exercised 2,419 restricted stock units
@ $0 |
|
| 05/19/2023 |
4
| Feener Edward P. (Chief Scientific Officer) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Sold 1,786 shares
@ $10.1444, valued at
$18.1k
Granted 29,166 restricted stock units
@ $0
Exercised 2,431 restricted stock units
@ $0
Exercised 1,774 restricted stock units
@ $0 |
|
| 05/19/2023 |
4
| Crockett Thomas Andrew (CEO) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Sold 5,627 shares
@ $10.1444, valued at
$57.1k
Granted 83,334 restricted stock units
@ $0
Exercised 6,945 restricted stock units
@ $0
Exercised 5,805 restricted stock units
@ $0 |
|
| 05/19/2023 |
4
| Audhya Paul K. (Chief Medical Officer) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Sold 2,780 shares
@ $10.1444, valued at
$28.2k
Granted 48,334 restricted stock units
@ $0
Exercised 4,028 options to buy
@ $0
Exercised 2,419 restricted stock units
@ $0 |
|
| 03/10/2023 |
SC 13G
| SUVRETTA CAPITAL MANAGEMENT, LLC reports a 5.3% stake in KalVista Pharmaceuticals, Inc. |
| 03/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"KalVista Pharmaceuticals Inc. Condensed Consolidated Balance Sheets January 31, April 30, 2023 2022 Assets Current assets: Cash and cash equivalents $ 85,049 $ 30,732 Marketable securities 86,636 135,470 Research and development tax credit receivable 11,892 14,098 Prepaid expenses and other current assets 8,556 13,347 Total current assets 192,133 193,647 Property and equipment, net 3,037 2,178 Right of use assets 8,101 7,862 Other assets 197 193 Total assets $ 203,468 $ 203,880 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,698 $ 3,638 Accrued expenses 8,851 6,961 Lease liability - current portion 1,057 977 Total current liabilities 11,606 11,576 Long-term liabilities: Lease liability - net of current portion 7,421 7,211 Total long-term liabilities 7,421 7,..." |
|
| 02/23/2023 |
4
| Audhya Paul K. (Chief Medical Officer) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Sold 3,412 shares
@ $7.66, valued at
$26.1k
Exercised 4,027 options to buy
@ $0
Exercised 2,419 restricted stock units
@ $0 |
|
| 02/23/2023 |
4
| Feener Edward P. (Chief Scientific Officer) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Sold 2,228 shares
@ $7.66, valued at
$17.1k
Exercised 2,430 options to buy
@ $0
Exercised 1,774 restricted stock units
@ $0 |
|
| 02/23/2023 |
4
| Yea Christopher (Chief Development Officer) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Sold 2,727 shares
@ $7.66, valued at
$20.9k
Exercised 2,430 options to buy
@ $0
Exercised 1,774 restricted stock units
@ $0 |
|
| 02/23/2023 |
4
| Palleiko Benjamin L (President, CFO, CBO & Sec'y) has filed a Form 4 on KalVista Pharmaceuticals, Inc.|
Txns:
| Sold 4,954 shares
@ $7.66, valued at
$37.9k
Exercised 6,944 options to buy
@ $0
Exercised 2,419 restricted stock units
@ $0 |
|
|
|
|